These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31275864)

  • 1. Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus.
    Ripoll DR; Wallqvist A; Chaudhury S
    Front Cell Infect Microbiol; 2019; 9():200. PubMed ID: 31275864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
    Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
    Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.
    de Alwis R; Williams KL; Schmid MA; Lai CY; Patel B; Smith SA; Crowe JE; Wang WK; Harris E; de Silva AM
    PLoS Pathog; 2014 Oct; 10(10):e1004386. PubMed ID: 25275316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reacting antibodies enhance dengue virus infection in humans.
    Dejnirattisai W; Jumnainsong A; Onsirisakul N; Fitton P; Vasanawathana S; Limpitikul W; Puttikhunt C; Edwards C; Duangchinda T; Supasa S; Chawansuntati K; Malasit P; Mongkolsapaya J; Screaton G
    Science; 2010 May; 328(5979):745-8. PubMed ID: 20448183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
    Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.
    Cui G; Si L; Wang Y; Zhou J; Yan H; Jiang L
    J Gene Med; 2021 Feb; 23(2):e3297. PubMed ID: 33217097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
    Renner M; Flanagan A; Dejnirattisai W; Puttikhunt C; Kasinrerk W; Supasa P; Wongwiwat W; Chawansuntati K; Duangchinda T; Cowper A; Midgley CM; Malasit P; Huiskonen JT; Mongkolsapaya J; Screaton GR; Grimes JM
    Nat Immunol; 2018 Nov; 19(11):1248-1256. PubMed ID: 30323338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity.
    Dent M; Hurtado J; Paul AM; Sun H; Lai H; Yang M; Esqueda A; Bai F; Steinkellner H; Chen Q
    J Gen Virol; 2016 Dec; 97(12):3280-3290. PubMed ID: 27902333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection.
    Wang Y; Si LL; Guo XL; Cui GH; Fang DY; Zhou JM; Yan HJ; Jiang LF
    Virus Res; 2017 Feb; 229():57-64. PubMed ID: 27939945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.